Stay updated with breaking news from Merck Sharp. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.
/PRNewswire/ -- DelveInsight's High-grade Glioma Market Insights report includes a comprehensive understanding of current treatment practices, high-grade...
The first study to deliberately infect people with Zika virus suggests that this strategy could help to test vaccines. Plus, a gigantic plan to link India’s rivers could reduce rainfall in already arid regions and how scientists are studying the evolution of the city mouse. The first study to deliberately infect people with Zika virus suggests that this strategy could help to test vaccines. Plus, a gigantic plan to link India’s rivers could reduce rainfall in already arid regions and how scientists are studying the evolution of the city mouse.
Enfortumab vedotin plus pembrolizumab improved survival outcomes over chemotherapy in previously untreated, advanced bladder cancer.
Belzutifan significantly reduced the risk of progression of clear cell renal cell carcinoma (ccRCC), the most common type of kidney cancer, in patients previously treated with immune checkpoint inhibitors and anti-angiogenic therapies compared with everolimus in a phase 3 clinical trial.
Two randomized trials highlighted the benefit of adding immune checkpoint inhibitors to neoadjuvant chemotherapy in patients with early high-risk estrogen receptor–positive, HER2-negative breast cancer.